Table 2 Colocalization of oestrogen and progesterone receptors with GABAB and mGluR2/3 receptors in the hippocampi of females Proechimys guyannensis.

From: Hormonal and biochemical changes in female Proechimys guyannensis, an animal model of resistance to pilocarpine-induced status epilepticus

Groups

GABAB

mGluR2/3

CA1

CA3

DG

Hilus

CA1

CA3

DG

Hilus

ER-alpha

CTR-NOVX

0.77 ± 0.005

0.81 ± 0.01

0.72 ± 0.01

0.73 ± 0.005

0.34 ± 0.01

0.54 ± 0.01

0.46 ± 0.03

0.64 ± 0.006

CTR-OVX

0.87 ± 0.005

0.76 ± 0.03

0.80 ± 0.006

0.60 ± 0.006

0.59 ± 0.006

0.55 ± 0.01

0.68 ± 0.01

0.58 ± 0.01

PILO 30-NOVX

0.78 ± 0.01

0.78 ± 0.01

0.46 ± 0.02**

0.47 ± 0.005**

0.58 ± 0.06

0.60 ± 0.006

0.55 ± 0.07

0.64 ± 0.006

PILO 30-OVX

0.75 ± 0.004

0.81 ± 0.006

0.72 ± 0.01

0.73 ± 0.01

0.63 ± 0.01

0.53 ± 0.06

0.53 ± 0.05**

0.48 ± 0.08

PILO 90-NOVX

0.76 ± 0.01

0.82 ± 0.03

0.68 ± 0.01

0.72 ± 0.005

0.66 ± 0.01**

0.65 ± 0.006**

0.71 ± 0.006**

0.60 ± 0.006

PILO 90-OVX

0.71 ± 0.03*

0.74 ± 0.01

0.66 ± 0.01**

0.78 ± 0.03**

0.54 ± 0.01##

0.50 ± 0.006

0.62 ± 0.006

0.48 ± 0.02

ER-beta

CTR-NOVX

0.05 ± 0.005

0.18 ± 0.01

0.05 ± 0.006

0.04 ± 0.006

0.23 ± 0.08

0.22 ± 0.01

0.35 ± 0.06

0.22 ± 0.01

CTR-OVX

0.40 ± 0.002

0.43 ± 0.01

0.46 ± 0.006

0.43 ± 0.006

0.21 ± 0.01

0.39 ± 0.05

0.36 ± 0.03

0.23 ± 0.01

PILO 30-NOVX

0.27 ± 0.01**

0.35 ± 0.006**

0.19 ± 0.01

0.28 ± 0.05*

0.07 ± 0.01*

0.21 ± 0.01

0.24 ± 0.02

0.24 ± 0.01

PILO 30-OVX

0.20 ± 0.006*

0.21 ± 0.006*

0.38 ± 0.01

0.26 ± 0.03

0.19 ± 0.01

0.26 ± 0.02**

0.24 ± 0.02

0.24 ± 0.01

PILO 90-NOVX

0.17 ± 0.02

0.29 ± 0.03

0.29 ± 0.01**

0.25 ± 0.06

0.15 ± 0.01

0.29 ± 0.01#

0.24 ± 0.01

0.23 ± 0.01

PILO 90-OVX

0.21 ± 0.01*

0.25 ± 0.006

0.26 ± 0.01**

0.19 ± 0.01**

0.19 ± 0.01

0.33 ± 0.01

0.24 ± 0.00

0.20 ± 0.01

Progesterone

CTR-NOVX

0.37 ± 0.006

0.51 ± 0.07

0.35 ± 0.01

0.40 ± 0.01

0.20 ± 0.003

0.38 ± 0.02

0.44 ± 0.01

0.24 ± 0.01

CTR-OVX

0.46 ± 0.01

0.55 ± 0.02

0.57 ± 0.04

0.90 ± 0.006

0.36 ± 0.1

0.54 ± 0.005

0.50 ± 0.07

0.58 ± 0.01

PILO 30-NOVX

0.37 ± 0.006

0.52 ± 0.01

0.05 ± 0.006**

0.48 ± 0.09

0.29 ± 0.01

0.63 ± 0.09

0.36 ± 0.006

0.67 ± 0.01*

PILO 30-OVX

0.42 ± 0.01

0.46 ± 0.01

0.09 ± 0.005

0.81 ± 0.01**

0.75 ± 0.02

0.48 ± 0.03

0.76 ± 0.01

0.57 ± 0.006

PILO 90-NOVX

0.27 ± 0.02

0.43 ± 0.005

0.06 ± 0.006

0.46 ± 0.005

0.35 ± 0.01**

0.34 ± 0.01##

0.40 ± 0.02

0.73 ± 0.006**

PILO 90-OVX

0.40 ± 0.02

0.42 ± 0.01**

0.08 ± 0.005*

0.89 ± 0.006

0.24 ± 0.01##

0.39 ± 0.02**

0.30 ± 0.03#

0.44 ± 0.01*

  1. ER-alpha: Oestrogen receptor alpha; ER-beta: Oestrogen receptor beta; GABAB: Gamma-aminobutyric acid; mGluR2/3: Metabotropic glutamate receptor; CTR-NOVX: Non-ovariectomised control group, animals no submitted to SE; CTR-OVX: Ovariectomised control group, animals no submitted to SE; PILO 30-NOVX, Non-ovariectomised animals analysed 30 min after SE onset; PILO 30-OVX: Ovariectomised animals analysed 30 min after SE onset; PILO 90-NOVX, Non-ovariectomised animals analysed 90 min after SE onset; PILO 90-OVX: Ovariectomised animals analysed 90 min after SE onset. Data are presented as mean ± SD. Kruskal–Wallis test followed by Dunn’s post hoc test. *p < 0.05, **p < 0.01 versus CTR-NOVX or CTR-OVX. #p < 0.05, ##p < 0.01 versus PILO 30-NOVX or PILO 30-OVX.